MIMETAS

mimetas-logo

MIMETAS develops predictive Organ-on-a-Chip cell culture models for better, more reliable and tailored medicines. A significant gap exist between the predictive value of various in vitro and animal screening models and a patient. MIMETAS fills this gap with its OrganoPlates featuring organotypic screening models that have an improved predictability and can be screened at a high throughput.

#People #Financial #Website #More

MIMETAS

Industry:
3D Technology Biotechnology Health Care Information Technology

Founded:
2013-01-01

Address:
Leiden, Zuid-Holland, The Netherlands

Country:
The Netherlands

Website Url:
http://www.mimetas.com

Total Employee:
101+

Status:
Active

Contact:
(318) 588-8316

Email Addresses:
[email protected]

Total Funding:
32.36 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Content Delivery Network JsDelivr Facebook Sharer Amazon Virginia Region Pardot LiveChat Lighttpd


Current Employees Featured

jos-joore_image

Jos Joore
Jos Joore CEO and Co-Founder @ Mimetas
CEO and Co-Founder
2010-10-01

paul-vulto_image

Paul Vulto
Paul Vulto CEO and Co-Founder @ Mimetas
CEO and Co-Founder
2011-10-01

thomas-hankemeier_image

Thomas Hankemeier
Thomas Hankemeier Co-Founder @ Mimetas
Co-Founder
2013-01-01

anthony-saleh_image

Anthony Saleh
Anthony Saleh Director Product R&D @ Mimetas
Director Product R&D
2016-01-01

eric-van-der-putten_image

Eric van der Putten
Eric van der Putten Non Executive Director @ Mimetas
Non Executive Director
2018-07-01

dwayne-dexter_image

Dwayne Dexter
Dwayne Dexter Director, Mimetas US @ Mimetas
Director, Mimetas US
2018-01-01

bas-trietsch_image

Bas Trietsch
Bas Trietsch Chief Technology Officer @ Mimetas
Chief Technology Officer
2017-12-01

sander-de-vos_image

Sander de Vos
Sander de Vos Director of Sales @ Mimetas
Director of Sales

Founder


jos-joore_image

Jos Joore

paul-vulto_image

Paul Vulto

thomas-hankemeier_image

Thomas Hankemeier

Investors List

easme_image

EASME - EU Executive Agency for SMEs

EASME - EU Executive Agency for SMEs investment in Grant - Mimetas

european-life-sciences-growth-fund_image

European Life Sciences Growth Fund

European Life Sciences Growth Fund investment in Series B - Mimetas

oostnl_image

OostNL

OostNL investment in Series B - Mimetas

cathay-venture_image

Cathay Venture

Cathay Venture investment in Series B - Mimetas

korys_image

Korys

Korys investment in Series B - Mimetas

innovation-quarter_image

InnovationQuarter

InnovationQuarter investment in Series B - Mimetas

aglaia-biomedical-ventures_image

Aglaia BioMedical Ventures

Aglaia BioMedical Ventures investment in Series B - Mimetas

pmv-eu_image

PMV

PMV investment in Series A - Mimetas

zeeuws-investerings-fonds_image

Zeeuws Investerings Fonds

Zeeuws Investerings Fonds investment in Series A - Mimetas

Official Site Inspections

http://www.mimetas.com Semrush global rank: 3.63 M Semrush visits lastest month: 3.93 K

  • Host name: 104.21.16.16
  • IP address: 104.21.16.16
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Mimetas"

Human Tissue Models for Better Therapies - MIMETAS

Discover our mission, vision, company history, and core values that drive innovation at MIMETAS. Using our OrganoCore ® Discovery Platform, we create robust and screenable assays for …See details»

MIMETAS - Wikipedia

Mimetas is a privately owned biotechnology company developing human organ-on-a-chip tissue models and products for drug development. The company also is involved in the testing of chemicals along with food and personalized medicine applications. The company is based in Oegstgeest and Enschede, The Netherlands, with subsidiairies in Gaithersburg (MD), United States, and Tokyo, Japan. Mimetas was founded in 2011 by Paul Vulto, Jos Joore, Bas Trietsch and Th…See details»

About Us - MIMETAS

MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds. As an extension of your team, MIMETAS provides the expertise and resources needed for effective research …See details»

Services - MIMETAS

MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds. As an extension of your team, MIMETAS provides the expertise and …See details»

MIMETAS - LinkedIn

By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to...See details»

MIMETAS Company Profile 2024: Valuation, Funding

Developer of organ-on-a-chip products designed for compound testing, screening, and fundamental research.See details»

Mimetas - Crunchbase Company Profile & Funding

MIMETAS develops predictive Organ-on-a-Chip cell culture models for better, more reliable and tailored medicines. A significant gap exist between the predictive value of various in vitro and animal screening models and a patient.See details»

MIMETAS - LinkedIn

By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative …See details»

Mimetas B.V. | Scientist.com

As true pioneers in organ-on-a-chip biology, MIMETAS is proud to offer high-throughput human tissue and disease models in OrganoPlates®. OrganoPlates® are microfluidic 3D culture plates, supporting up to 96 tissue models on a …See details»

MIMETAS Elected Most Innovative Company of the …

As the 2022 award winner, MIMETAS succeeds ASML, today’s global leader in semiconductor equipment and Europe’s largest high-tech company. MIMETAS (Leiden, The Netherlands) is a global leader in human-relevant disease …See details»

MIMETAS: QMUL Centre for Predictive in vitro Models

MIMETAS is a global leader in human tissue and disease modeling, using its organ-on-a-chip technology to develop physiologically relevant 3D in vitro models without the need of …See details»

Future Organ-on-a-chip Global Leader MIMETAS raised 4 Million …

Oct 13, 2014 · Dutch biotech MIMETAS B.V. announces that it has raised 4 Million euros ($5.2M) to fund its expansion as a global leader in organ-on-a-chip technology.See details»

Mimetas - Lifesciences @ Work

As true pioneers in organ-on-a-chip biology, we are proud to develop any-throughput human tissue and disease models in the OrganoPlate ® for the industry. Our vision is to create the …See details»

MIMETAS - Technology Networks

MIMETAS strives to contribute to groundbreaking therapies with unique human disease biology, revealed by robust, screenable assays in the most versatile technology platform. By combining …See details»

MIMETAS - Human Tissue Models for Better Therapies - YouTube

MIMETAS' OrganoPlate® serves as an early stage screening model to predict toxic side effects and drug efficacy.See details»

Team - MIMETAS

MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds. As an extension of your team, MIMETAS provides the expertise and …See details»

MIMETAS and Astellas Enter into Strategic Partnership on Immuno ...

Mar 28, 2023 · MIMETAS, a human disease model provider, entered into a strategic partnership with Astellas Pharma Inc. The partnership comprises utilizing MIMETAS’ comprehensive …See details»

MIMETAS organ-on-a-chip technology

OrganoPlate ® is a microfluidic 3D tissue culture plate, supporting up to 96 tissue models on a single plate. Its unique PhaseGuide tm technology enables cells to interact and migrate freely …See details»

Partners and projects with Mimetas involvement — Mimeta

Jun 13, 2024 · In 2020 we will hopefully be able to provide organizational support to our established partners in MENA and Africa South of Sahara so that they will be able to continue …See details»

Mimeta

Mimetas vision is to give GIVE PEOPLE THEIR RIGHT TO FREE CREATIVE EXPRESSIONS, created on free terms and presented by independent institutions. Our mission is to support and …See details»

linkstock.net © 2022. All rights reserved